concern
safeti
adequaci
blood
suppli
foster
twenti
year
research
socal
blood
substitut
among
oxygen
carrier
base
modifi
hemoglobin
although
none
materi
yet
licens
use
north
america
europ
result
research
clinic
trial
increas
understand
oxygen
deliveri
regul
particular
examin
basi
vasoact
observ
hemoglobin
base
oxygen
carrier
led
insight
sever
collig
properti
hemoglobin
solut
diffus
coeffici
oxygen
viscos
colloid
oncot
pressur
import
determin
efficaci
two
major
impuls
drive
develop
blood
substitut
concern
infecti
risk
transfus
adequaci
blood
suppli
although
incid
transfus
transmit
hiv
hepat
b
viru
hepat
c
viru
greatli
reduc
sinc
threat
new
emerg
pathogen
west
nile
viru
corona
viru
respons
sever
acut
respiratori
syndrom
continu
motiv
research
oxygen
carrier
free
infecti
agent
furthermor
episod
blood
shortag
gap
grow
transfus
need
age
popul
expect
access
increasingli
sophist
medic
care
shrink
proport
public
will
abl
donat
blood
make
synthet
semisynthet
oxygen
carrier
desir
adjunct
bank
blood
three
major
class
materi
studi
blood
substitut
perfluorocarbon
emuls
modifi
hemoglobin
solut
liposomeenclos
hemoglobin
perfluorocarbon
emuls
modifi
hemoglobin
solut
reach
level
clinic
trial
liposomeenclos
hemoglobin
remain
preclin
stage
test
number
review
discuss
variou
aspect
blood
substitut
review
focu
hemoglobinbas
oxygen
carrier
hboc
hemoglobin
obviou
candid
blood
substitut
number
desir
characterist
high
capac
lack
numer
complex
antigen
red
blood
cell
membran
henc
univers
compat
robust
molecul
withstand
rigor
purif
viral
inactiv
process
stabl
ordinari
storag
condit
physiolog
thought
well
understood
although
time
shown
learn
thu
eight
differ
compani
embark
develop
hboc
see
tabl
date
one
product
oxyglobin
licens
veterinari
use
sister
product
hemopur
approv
limit
use
human
south
africa
howev
three
compani
still
activ
engag
clinic
trial
hboc
northfield
biopur
sangart
hemassistbaxterhemassist
human
hemoglobin
tetram
stabil
diaspirin
linkag
phase
iii
clinic
trial
trauma
surgeri
acut
ischem
stroke
compani
halt
develop
stroke
trauma
trial
excess
mortal
observ
among
patient
receiv
hemassist
compar
receiv
bank
red
blood
cell
howev
mortal
equival
among
patient
receiv
hemassist
bank
red
blood
cell
trial
cardiac
surgeri
posthoc
analysi
trauma
trial
fail
identifi
reason
unexpect
high
mortal
rate
hemassist
treat
patient
subsequ
howev
studi
publish
compar
resuscit
normal
salin
diaspirin
crosslink
hemoglobin
tetram
hemassist
anim
model
traumat
brain
injuri
mean
arteri
pressur
higher
cardiac
output
lower
hemoglobinresuscit
anim
addit
cerebr
satur
lower
suggest
deliveri
impair
perhap
result
vasoconstrict
respons
hboc
hemolinkhemosolthi
product
consist
human
hemoglobin
polymer
use
oxid
trisaccharid
oraffinos
follow
reduct
step
studi
phase
ii
clinic
trial
dialysi
oxygen
carri
replac
fluid
acut
normovolem
hemodilut
note
mild
system
pressor
effect
phase
ii
iii
studi
cardiac
surgeri
patient
receiv
unit
hemolink
requir
fewer
transfus
bank
red
blood
cell
day
surgeri
compar
control
receiv
pentastarch
howev
compani
announc
safeti
concern
phase
iii
studi
sinc
initi
new
trial
product
hemopurebiopurehemopur
veterinari
formul
oxyglobin
consist
bovin
hemoglobin
polymer
glutaraldehyd
purifi
reduc
residu
hemoglobin
tetram
studi
princip
periop
use
bridg
defer
need
bank
red
blood
cell
also
note
pressor
effect
correl
increas
system
vascular
resist
decreas
cardiac
index
studi
patient
undergo
infraren
aortic
aneurysm
resect
patient
random
receiv
hemopur
intraop
avoid
allogen
transfus
compar
none
patient
receiv
bank
red
blood
cell
although
median
number
allogen
unit
use
differ
biopur
also
complet
phase
iii
studi
noncardiac
surgeri
submit
data
fda
request
addit
data
biopur
sinc
propos
phase
iibiii
clinic
trial
trauma
although
studi
design
yet
approv
fda
meanwhil
begun
explor
use
hemopur
cardioprotect
agent
patient
undergo
coronari
arteri
angioplasti
stent
placement
complet
enrol
clinic
trial
europ
polyhemenorthfieldthi
prepar
consist
human
hemoglobin
pyridoxil
increas
p
polymer
glutaraldehyd
purifi
remov
residu
tetram
develop
altern
bank
red
blood
cell
surgeri
trauma
northfield
submit
data
phase
iii
trial
trauma
fda
subsequ
initi
new
phase
iii
trial
polyhem
prehospit
trauma
resuscit
enrol
patient
plan
hemospansangartth
newest
hboc
clinic
trial
prepar
conjug
polyethylen
glycol
peg
human
hemoglobin
product
design
low
p
larg
molecular
diamet
high
viscos
phase
ii
trial
complet
europ
anoth
phase
ii
trial
initi
unit
state
although
hboc
develop
almost
year
product
yet
licens
human
use
except
limit
arrang
hemopur
south
africa
nonetheless
consider
progress
made
develop
product
meet
mani
criteria
clinic
use
safe
oxygen
carrier
includ
better
shelf
stabil
bank
red
cell
univers
compat
use
vascular
halflif
absenc
infecti
agent
avoid
known
toxic
relat
residu
stroma
absenc
renal
impair
hboc
develop
vascular
halfliv
h
rang
adequ
acut
care
applic
ie
hemorrhag
surgeri
store
room
temperatur
year
none
requir
form
compat
test
success
process
elimin
presenc
microorgan
although
publish
data
remov
prion
none
hboc
produc
acut
renal
injuri
seen
unmodifi
hemoglobin
present
vascular
space
howev
preclin
case
clinic
test
hboc
rais
safeti
concern
relat
vasoact
cell
toxic
latter
either
direct
effect
one
mediat
oxid
product
variou
hboc
develop
shown
system
pressor
effect
case
pulmonari
pressor
effect
well
usual
accompani
decreas
heart
rate
cardiac
output
indic
increas
system
vascular
resist
although
observ
system
pressor
effect
hboc
gener
mild
necessarili
deleteri
per
se
possibl
reflect
vasoconstrict
concern
particularli
prevent
effect
perfus
capillari
bed
elimin
benefit
increas
blood
pressur
increas
carri
capac
hboc
system
pressor
effect
shown
produc
vasoconstrict
anim
model
system
understand
mechan
wherebi
hboc
exert
pressor
effect
progress
consider
past
decad
rapid
bind
nitric
oxid
oxyand
deoxyhemoglobin
abil
hboc
small
compar
intact
erythrocyt
move
bloodstream
rbc
free
zone
close
vessel
wall
suggest
may
trigger
vasoconstrict
scaveng
produc
vascular
endothelium
therebi
releas
constitut
vasodilatori
influenc
predict
hboc
larg
molecular
weight
would
abl
extravas
subendotheli
space
readili
would
exert
less
vasoconstrict
effect
howev
correl
pressor
effect
molecular
weight
weak
although
substanti
pressor
effect
seen
stabil
hemoglobin
tetram
diaspirin
link
hemoglobin
hemassist
also
present
formul
consist
almost
entir
higher
order
nmer
hemoglobin
littl
residu
tetram
polyhem
hemopur
pressor
effect
also
correl
well
affin
therefor
scaveng
seem
major
mechan
wherebi
hboc
exert
vasoconstrict
effect
properti
hboc
emerg
import
determin
abil
deliv
oxygen
tissu
among
viscos
hemoglobin
solut
much
less
viscou
whole
blood
insofar
dilut
circul
blood
hboc
would
lower
viscos
system
vascular
resist
might
expect
improv
flow
least
system
level
howev
event
level
microcircul
may
necessarili
reflect
system
hemodynam
endotheli
cell
line
small
vessel
appear
sens
shear
stress
properti
move
fluid
directli
proport
viscos
drop
shear
stress
viscos
trigger
downregul
product
endotheli
cell
trigger
vasoconstrict
viscositydepend
regul
flow
microcircul
demonstr
sever
experiment
system
shear
stress
affect
blood
viscos
colloid
oncot
pressur
cop
well
viscos
q
net
vascular
fluid
movement
function
cop
blood
vessel
diamet
hboc
high
cop
high
viscos
would
expect
maintain
high
level
shear
stress
vasodil
state
addit
hboc
high
cop
would
expect
maintain
intravascular
volum
cardiac
output
contribut
mainten
normovolemia
system
level
perhap
microcircul
well
maintain
shear
stress
even
face
hemodilut
normal
hemoglobin
concentr
hboc
consist
polymer
hemoglobin
tetram
lower
cop
consist
stabil
hemoglobin
tetram
surfac
conjug
might
effect
maintain
intravascular
volum
flow
though
microcircul
base
observ
termin
arteriol
innerv
guyton
origin
propos
may
play
activ
role
regul
blood
flow
capillari
bed
suppli
recent
year
detail
autoregulatori
theori
propos
base
observ
anim
experi
model
system
theori
posit
termin
arteriol
respond
local
po
match
flow
perceiv
need
paradox
excess
deliveri
level
arteriol
might
expect
trigger
vasoconstrict
therebi
imped
flow
oxygen
deliveri
distal
capillari
bed
oxygen
deliveri
arteriol
may
affect
content
blood
turn
depend
hemoglobin
concentr
degre
satur
abil
hemoglobin
offload
determin
part
p
hill
coeffici
abil
diffus
red
cell
oxygen
carrier
vascular
endothelium
autoregulatori
theori
support
sever
key
observ
progress
drop
po
blood
flow
along
arteri
tree
capillari
bed
well
recogn
howev
loss
particularli
mark
level
vasoact
termin
arteriol
po
gener
approxim
mmhg
correspond
steep
portion
oxyhemoglobin
dissoci
curv
addit
extens
experiment
anim
model
system
shown
hboc
unload
level
precapillari
arteriol
trigger
vasoconstrict
consist
autoregulatori
model
sever
characterist
hboc
may
affect
propens
deliv
arteri
wall
presenc
hemoglobin
solut
known
enhanc
diffus
well
uptak
releas
hboc
distribut
red
cell
free
layer
plasma
close
endothelium
shorten
diffus
path
offload
well
facilit
diffus
red
blood
cell
plasma
toward
endothelium
sinc
diffus
coeffici
molecul
invers
relat
molecular
radiu
molecul
small
radiu
stabil
hemoglobin
tetram
would
higher
diffus
coeffici
hemoglobin
conjug
peg
complex
water
sweep
much
larger
radiu
hboc
high
diffus
coeffici
might
expect
deliv
arteri
wall
readili
accordingli
hboc
smaller
molecular
radii
presum
higher
diffus
coeffici
shown
produc
vasoconstrict
limit
blood
flow
distal
capillari
bed
sever
experiment
system
anoth
factor
could
affect
deliveri
arteri
wall
oxygen
affin
hboc
might
expect
hboc
high
oxygen
affin
low
p
would
unload
less
one
low
affin
therefor
less
like
trigger
vasoconstrict
respons
one
model
system
vasoact
found
greater
hboc
higher
p
similar
prepar
low
p
howev
experi
artifici
capillari
system
anim
indic
diffus
properti
hboc
make
contribut
vasoact
p
henc
p
seem
play
secondari
role
determin
vasoact
hboc
studi
suggest
hboc
high
viscos
high
cop
larg
molecular
radiu
low
diffus
coeffici
less
like
trigger
vasoconstrict
respons
improv
flow
oxygen
deliveri
capillari
bed
deleteri
effect
note
clinic
trial
includ
system
pressor
effect
may
reflect
region
vasoconstrict
impair
tissu
oxygen
search
clinic
use
oxygen
carrier
proven
arduou
timeconsum
howev
studi
variou
hboc
past
decad
reshap
think
mechan
oxygen
deliveri
regul
new
insight
pave
way
realiz
goal
ad
blood
substitut
therapeut
armamentarium
